In recent developments, Catalyst Pharmaceuticals has announced the publication of Santhera Pharmaceuticals’ VISION-DMD study results in the esteemed peer-reviewed journal, Neurology. The study elucidated the 48-week treatment outcomes of vamorolone, also known as AGAMREE, in patients suffering from Duchenne Muscular Dystrophy (DMD). These findings reinforce the drug’s advantageous long-term efficacy and safety profile, showcasing its potential as a game-changer in the treatment of this debilitating condition.
Duchenne Muscular Dystrophy (DMD) is a rare and progressive genetic disorder that primarily affects young boys, causing muscle degeneration and loss of mobility over time. Presently, there is no cure for DMD, and available treatments aim to alleviate symptoms and enhance quality of life.
Santhera Pharmaceuticals initiated the VISION-DMD study to assess the effectiveness of vamorolone, a novel glucocorticoid receptor agonist, in comparison to standard corticosteroid treatments such as prednisone or deflazacort. Previous studies had shown that traditional corticosteroids produced substantial side effects, including weight gain, bone fragility, and growth retardation.
The VISION-DMD study included a 48-week treatment phase involving children aged 4 to
Comments